Detalhe da pesquisa
1.
Vascular endothelial hyperpermeability induces the clinical symptoms of Clarkson disease (the systemic capillary leak syndrome).
Blood
; 119(18): 4321-32, 2012 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-22411873
2.
Immunoglobulin D amyloidosis: a distinct entity.
Blood
; 119(1): 44-8, 2012 Jan 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-22065594
3.
Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial.
Blood
; 119(21): 4860-7, 2012 May 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-22504925
4.
Reduction in plasma cell proliferation after initial therapy in newly diagnosed multiple myeloma measures treatment response and predicts improved survival.
Blood
; 118(10): 2702-7, 2011 Sep 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-21750316
5.
Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma.
Blood
; 118(7): 1763-5, 2011 Aug 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-21673347
6.
Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone.
Blood
; 118(16): 4359-62, 2011 Oct 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-21860025
7.
The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome.
Blood
; 118(17): 4663-5, 2011 Oct 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-21881050
8.
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease.
Blood
; 118(11): 2970-5, 2011 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21690557
9.
The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome.
Blood
; 115(14): 2827-34, 2010 Apr 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-19965618
10.
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients.
Blood
; 115(7): 1343-50, 2010 Feb 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-20008302
11.
Trends and outcomes of modern staging of solitary plasmacytoma of bone.
Am J Hematol
; 87(7): 647-51, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22549792
12.
Impact of high-risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03.
Br J Haematol
; 155(3): 340-8, 2011 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-21902684
13.
Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone.
Blood
; 114(3): 518-21, 2009 Jul 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-19324902
14.
Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature.
Ann Hematol
; 90(1): 101-6, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-20645101
15.
Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial.
Am J Hematol
; 86(8): 640-5, 2011 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-21630308
16.
Narrative review: the systemic capillary leak syndrome.
Ann Intern Med
; 153(2): 90-8, 2010 Jul 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-20643990
17.
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.
Lancet Oncol
; 11(1): 29-37, 2010 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-19853510
18.
Appraisal of immunoglobulin free light chain as a marker of response.
Blood
; 111(10): 4908-15, 2008 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18364469
19.
Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma.
Am J Hematol
; 85(10): 737-40, 2010 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-20730790
20.
Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma.
Am J Hematol
; 85(9): 664-9, 2010 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-20645430